메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

"Senior Speed Stack" Introduces Emerging Sport Stacking to H…

Key Points: The Junior Chamber International (JCI) North District organized the "2025 Senior Speed Stack Closing Ceremony," introducing sport stacking to help delay cognitive decline in the elderly. Celebrity Tiffany Lau (Tiffany) participated in speed stacking activities with seniors. Assistant Professor of Teaching Senior Dr Mok Kam-Ming from Lingnan University's School of Interdisciplinary Studies, conducted a tracking study as part of the project, finding that seniors who consistently participated in speed stacking training showed a downward trend in stress and anxi
- 김갑성 기자
- 2025-08-11 19:17
Everest Medicines to Announce 2025 Interim Results on Augu…

SHANGHAI, Aug. 11, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2025, and provide a business update on August 29, 2025. The Company will hold live conference calls in English and Mandarin on August 29, 2025, Beijing Time. The English session of the conference call will be held at 8:00 AM on August 29, 2025, Beijing
- 김갑성 기자
- 2025-08-11 17:11
WuXi Biologics Launches HEK 293 Stable Cell Line Platform Wu…

WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Stable platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. SHANGHAI, Aug. 11, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293Stable, a new platform designed for the developm
- 김갑성 기자
- 2025-08-11 16:30
Zoomlion's Corporate-Named Satellite Enters Orbit, Marking a N…

RIZHAO, China, Aug. 11, 2025 -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion," 1157.HK) has reached a new milestone with the successful entry into orbit of the "Zoomlion" corporate-named satellite, the first of its kind in the global engineering machinery sector. At 00:31 Beijing time, the Geely Constellation Group 04 satellites were launched from the coastal waters near Rizhao, Shandong, China, using the Jielong-3 carrier rocket, with one satellite carrying the Zoomlion name. The "Zoomlion" satellite marks the company's ex
- 김갑성 기자
- 2025-08-11 16:26
Akeso Announces First Patient Dosed in Phase III Trial of Ivon…

HONG KONG, Aug. 11, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, in small cell lung cancer (SCLC). This study is designed to assess the efficacy and safety of ivonescimab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following standard concurrent chemoradiotherapy
- 김갑성 기자
- 2025-08-11 10:52
Philippines' AC Health partners with Singapore's ABC Impact in…

MANILA, Philippines, Aug. 11, 2025 -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact's entry into the Philippine healthcare sector, expanding its regional footprint. Under the agreement, ABC Impact will infuse primary capital for a c.16% minority stake in AC Health. The investment will support AC Health's vision of transforming healthcare for every Filipino by building a se
- 김갑성 기자
- 2025-08-11 10:31
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus:…

SINGAPORE, Aug. 11, 2025 -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], which debuted just months earlier, FibroSIGHT™ Plus introduces an additional feature of automated quantitative analysis of fibrosis - a key advancement that enables more consistent and precise characterization at diagnosis and tracking of fibrosis in patients with Metabolic Dysfunction-associated Steatohepatitis
- 김갑성 기자
- 2025-08-11 09:00
Brain Navi Biotechnology's NaoTrac performs first surgeries…

Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep experience in the Spanish medical market, but also due to the trust and commitment of their team. Brain Navi CEO Jerry Chen stated, "Brain Navi is proud to work alongside a partner that shares our vision of surgical innovation and desire to improve the well-being of patients continuously."&nbs
- 김갑성 기자
- 2025-08-11 09:00
Hugel launches botulinum toxin Letybo in Malaysia

- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical SEOUL, South Korea, Aug. 11, 2025 -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, has officially launched its botulinum toxin product Letybo in Malaysia – an emerging market for medical aesthetics in Southeast Asia. The company's Malaysian partner Venusys Medical Sdn Bhd introduced Letybo at the
- 김갑성 기자
- 2025-08-11 08:30
Anbio Biotechnology Responds to Global Outbreaks with Ch…

[ 메디채널 김갑성 기자 ] Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 9, 2025 -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral
- 김갑성 기자
- 2025-08-09 09:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분